Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

NCT ID: NCT03500731

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-19
• Study Completion Date: 2028-12-31

Brief Summary

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

Detailed Description

The primary purpose of the study is to evaluate the safety and efficacy of performing lung transplantation followed by cadaveric, partially HLA-matched (≥1/6 HLA-match with an identical ABO blood type) CD3+/CD19+ depleted bone marrow transplantation in bone marrow failure and end-stage lung disease. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal interstitial lung disease for which lung transplantation is the only therapy shown to prolong survival. Given the association of IPF with hematologic cytopenias and bone marrow failure, it is proposed that a tandem lung transplantation and bone marrow transplantation from a single cadaveric donor could be successful. This protocol focuses on performing combined transplantation for candidates that are unable to undergo standard lung transplantation. Lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, and to restore hematologic function post BMT transplantation. The secondary objectives are to evaluate the feasibility and long-term complications associated with combined solid organ and BMT including the ability to initiate and successfully withdraw from immunosuppression following BMT and to attain independence from growth factors, red blood cell or platelet transfusions.

Conditions

Idiopathic Pulmonary Fibrosis; Emphysema or COPD

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lung and Bone Marrow Transplantation

All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.

Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.

Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved.

Group Type: EXPERIMENTAL

G-CSF

Intervention Type: DRUG

Transplantation conditioning

Hydroxyurea

Intervention Type: DRUG

Transplantation Conditioning

Thiotepa

Intervention Type: DRUG

Transplantation Conditioning

CD3/CD19 negative hematopoietic stem cells

Intervention Type: BIOLOGICAL

Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation

Rituximab

Intervention Type: DRUG

Transplantation Conditioning

Alemtuzumab

Intervention Type: DRUG

Transplantation Conditioning

Fludarabine

Intervention Type: DRUG

Transplantation Conditioning

Interventions

G-CSF

Transplantation conditioning

Intervention Type: DRUG

Hydroxyurea

Transplantation Conditioning

Intervention Type: DRUG

Thiotepa

Transplantation Conditioning

Intervention Type: DRUG

CD3/CD19 negative hematopoietic stem cells

Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation

Intervention Type: BIOLOGICAL

Rituximab

Transplantation Conditioning

Intervention Type: DRUG

Alemtuzumab

Transplantation Conditioning

Intervention Type: DRUG

Fludarabine

Transplantation Conditioning

Intervention Type: DRUG

Other Intervention Names

Rituxan; Campath-1H; Fludara, Oforta; Neupogen, Granix, Zarxio, Filgrastim

Eligibility Criteria

Inclusion Criteria

Individuals must meet all of the following criteria in order to be eligible for this study.

1. Subject must be able to understand and provide informed consent.

2. Male or female, 18 through 60 years old, inclusive, at the time of informed consent.

3. Meet criteria for UNOS listing for lung transplantation.

4. Patients must have evidence of end stage lung disease. Examples of such diseases include but are not limited to:

• Pulmonary Fibrosis
• COPD/Emphysema

5. Patients must have evidence of bone marrow failure with abnormal low cell count in at least one hematopoietic line, making the patient a poor candidate for long-term immunosuppressive therapy. Eligible patients must meet at least one of the following criteria:

• Unexplained, non-drug induced neutropenia with absolute neutrophils counts of <1500/µL the previous year, confirmed by repeat testing
• Unexplained, non-drug induced thrombocytopenia with mean platelets counts of <100,000/µL the previous year, confirmed by repeat testing
• Unexplained, non-hemolytic anemia, with a hemoglobin level of < 12 g/dL the previous year, confirmed by repeat testing

6. GFR ≥45 mL/min/1.73 m2.

7. AST, ALT ≤4x upper limit of normal, total bilirubin ≤ 2.5 mg/dL, normal INR, albumin >3.0 g/dL

8. Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%.

9. Negative pregnancy test for females, unless surgically sterilized.

10. All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defect.

11. Subject will also be counseled regarding the potential risks of infertility following BMT and advised to discuss sperm banking or oocyte harvesting.

Exclusion Criteria

Individuals who meet any of these criteria are not eligible for this study.

1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol.

2. Patients who have underlying malignant conditions.

3. Patients who have non-malignant conditions not requiring BMT.

4. HIV positive by serology or PCR, HTLV positive by serology. If HTLV serology is positive, it will be confirmed by nucleic acid testing (NAT). If HTLV NAT is negative, subject will remain eligible regardless of HTLV serology result.

5. Females who are pregnant or who are lactating.

6. Allergy to DMSO or any other ingredient used in the manufacturing of the stem cell product.

7. Uncontrolled pulmonary infection, as determined by radiographic findings and/or significant clinical deterioration. NOTE: Pulmonary colonization with multiple organisms is common and will not be considered an exclusion criterion.

8. Uncontrolled infection, as determined by the appropriate imaging and/or confirmatory testing e.g. blood cultures, PCR testing, etc.

9. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of transplant.

10. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Paul Szabolcs

OTHER

Sponsor Role: lead

Responsible Party

Paul Szabolcs

Chief, Division of Blood and Marrow Transplantation and Cellular Therapy

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

UPMC Presbyterian

Pittsburgh, Pennsylvania, United States

Site Status: RECRUITING

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Paul Szabolcs, M.D.

Role: CONTACT

Paul.Szabolcs@chp.edu

412-692-5427

Shawna H McIntyre, RN

Role: CONTACT

mcintyresm@upmc.edu

412-692-5552 ext. 4126925552

Facility Contacts

John McDyer, MD

Role: primary

mcdyerjf@upmc.edu

412-648-6161

Shawna H McIntyre, RN

Role: primary

mcintyresm@upmc.edu

412-692-5552

Other Identifiers

STUDY19110120

Identifier Type: -

Identifier Source: org_study_id